Lucid Capital Surpluse vs Capital Stock Analysis

LUCD Stock

USD 0.79 0.02 2.60%

Lucid Diagnostics financial indicator trend analysis is infinitely more than just investigating Lucid Diagnostics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lucid Diagnostics is a good investment. Please check the relationship between Lucid Diagnostics Capital Surpluse and its Capital Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

Capital Surpluse vs Capital Stock

Capital Surpluse vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lucid Diagnostics Capital Surpluse account and Capital Stock. At this time, the significance of the direction appears to have pay attention.

The correlation between Lucid Diagnostics' Capital Surpluse and Capital Stock is -0.95. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Lucid Diagnostics, assuming nothing else is changed. The correlation between historical values of Lucid Diagnostics' Capital Surpluse and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Lucid Diagnostics are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Capital Surpluse i.e., Lucid Diagnostics' Capital Surpluse and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.95

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Capital Surpluse

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most indicators from Lucid Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lucid Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 17.1 M, whereas Selling General Administrative is forecasted to decline to about 13.1 M.

Lucid Diagnostics fundamental ratios Correlations

	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Total Assets	Other Current Liab	Total Stockholder Equity	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Net Receivables
Total Current Liabilities		-0.87	0.6	-0.89	0.65	0.37	0.67	0.44	0.78	-0.01	-0.03	0.37	0.57	0.79	-0.72	0.37	0.83	0.78	-0.07	0.66	0.91	0.98	-0.1	0.91	-0.1	0.24
Other Liab	-0.87		-0.68	0.82	-0.33	-0.28	-0.48	-0.36	-0.48	0.06	-0.05	-0.31	-0.41	-0.6	0.84	-0.31	-0.87	-0.72	0.1	-0.51	-0.95	-0.91	0.15	-0.95	0.14	-0.21
Net Tangible Assets	0.6	-0.68		-0.74	-0.08	-0.03	0.45	0.09	0.41	-0.24	0.31	-0.01	0.71	0.73	-0.49	-0.01	0.76	0.59	-0.55	0.28	0.71	0.69	-0.3	0.71	-0.35	-0.27
Retained Earnings	-0.89	0.82	-0.74		-0.5	-0.58	-0.88	-0.66	-0.54	-0.27	0.26	-0.58	-0.83	-0.94	0.58	-0.58	-0.73	-0.96	-0.06	-0.82	-0.88	-0.87	-0.18	-0.88	-0.16	-0.37
Accounts Payable	0.65	-0.33	-0.08	-0.5		0.56	0.58	0.57	0.62	0.34	-0.45	0.55	0.36	0.51	-0.11	0.55	0.16	0.52	0.38	0.6	0.34	0.52	0.31	0.33	0.3	0.5
Total Current Assets	0.37	-0.28	-0.03	-0.58	0.56		0.82	0.99	-0.05	0.92	-0.93	1.0	0.53	0.52	-0.08	1.0	-0.01	0.77	0.83	0.92	0.31	0.24	0.88	0.31	0.88	0.94
Common Stock	0.67	-0.48	0.45	-0.88	0.58	0.82		0.88	0.33	0.63	-0.62	0.81	0.88	0.9	-0.23	0.81	0.36	0.94	0.39	0.94	0.58	0.57	0.57	0.58	0.54	0.61
Total Assets	0.44	-0.36	0.09	-0.66	0.57	0.99	0.88		0.0	0.89	-0.89	0.99	0.62	0.61	-0.12	0.99	0.07	0.84	0.76	0.94	0.38	0.32	0.84	0.38	0.84	0.9
Other Current Liab	0.78	-0.48	0.41	-0.54	0.62	-0.05	0.33	0.0		-0.39	0.31	-0.07	0.33	0.58	-0.48	-0.07	0.68	0.34	-0.36	0.27	0.6	0.79	-0.44	0.6	-0.45	-0.17
Total Stockholder Equity	-0.01	0.06	-0.24	-0.27	0.34	0.92	0.63	0.89	-0.39		-0.99	0.92	0.39	0.27	0.26	0.92	-0.38	0.53	0.89	0.7	-0.06	-0.15	1.0	-0.06	0.99	0.89
Net Debt	-0.03	-0.05	0.31	0.26	-0.45	-0.93	-0.62	-0.89	0.31	-0.99		-0.93	-0.33	-0.25	-0.23	-0.93	0.37	-0.51	-0.93	-0.72	0.05	0.11	-0.98	0.05	-0.99	-0.92
Cash	0.37	-0.31	-0.01	-0.58	0.55	1.0	0.81	0.99	-0.07	0.92	-0.93		0.52	0.51	-0.1	1.0	0.0	0.78	0.83	0.91	0.33	0.25	0.88	0.32	0.88	0.95
Non Current Assets Total	0.57	-0.41	0.71	-0.83	0.36	0.53	0.88	0.62	0.33	0.39	-0.33	0.52		0.94	-0.07	0.52	0.35	0.84	0.0	0.69	0.49	0.52	0.34	0.49	0.28	0.22
Non Currrent Assets Other	0.79	-0.6	0.73	-0.94	0.51	0.52	0.9	0.61	0.58	0.27	-0.25	0.51	0.94		-0.33	0.51	0.58	0.9	-0.02	0.77	0.7	0.75	0.2	0.7	0.16	0.25
Other Assets	-0.72	0.84	-0.49	0.58	-0.11	-0.08	-0.23	-0.12	-0.48	0.26	-0.23	-0.1	-0.07	-0.33		-0.1	-0.91	-0.44	0.13	-0.36	-0.89	-0.8	0.34	-0.9	0.3	-0.13
Cash And Short Term Investments	0.37	-0.31	-0.01	-0.58	0.55	1.0	0.81	0.99	-0.07	0.92	-0.93	1.0	0.52	0.51	-0.1		0.0	0.78	0.83	0.91	0.33	0.25	0.88	0.32	0.88	0.95
Common Stock Shares Outstanding	0.83	-0.87	0.76	-0.73	0.16	-0.01	0.36	0.07	0.68	-0.38	0.37	0.0	0.35	0.58	-0.91	0.0		0.54	-0.39	0.35	0.94	0.92	-0.46	0.94	-0.45	-0.1
Short Term Investments	0.78	-0.72	0.59	-0.96	0.52	0.77	0.94	0.84	0.34	0.53	-0.51	0.78	0.84	0.9	-0.44	0.78	0.54		0.31	0.92	0.76	0.72	0.45	0.76	0.43	0.58
Non Current Liabilities Total	-0.07	0.1	-0.55	-0.06	0.38	0.83	0.39	0.76	-0.36	0.89	-0.93	0.83	0.0	-0.02	0.13	0.83	-0.39	0.31		0.59	-0.1	-0.19	0.89	-0.1	0.92	0.94
Other Current Assets	0.66	-0.51	0.28	-0.82	0.6	0.92	0.94	0.94	0.27	0.7	-0.72	0.91	0.69	0.77	-0.36	0.91	0.35	0.92	0.59		0.62	0.56	0.64	0.61	0.64	0.8
Other Stockholder Equity	0.91	-0.95	0.71	-0.88	0.34	0.31	0.58	0.38	0.6	-0.06	0.05	0.33	0.49	0.7	-0.89	0.33	0.94	0.76	-0.1	0.62		0.95	-0.15	1.0	-0.14	0.22
Total Liab	0.98	-0.91	0.69	-0.87	0.52	0.24	0.57	0.32	0.79	-0.15	0.11	0.25	0.52	0.75	-0.8	0.25	0.92	0.72	-0.19	0.56	0.95		-0.24	0.95	-0.24	0.12
Net Invested Capital	-0.1	0.15	-0.3	-0.18	0.31	0.88	0.57	0.84	-0.44	1.0	-0.98	0.88	0.34	0.2	0.34	0.88	-0.46	0.45	0.89	0.64	-0.15	-0.24		-0.16	1.0	0.86
Capital Stock	0.91	-0.95	0.71	-0.88	0.33	0.31	0.58	0.38	0.6	-0.06	0.05	0.32	0.49	0.7	-0.9	0.32	0.94	0.76	-0.1	0.61	1.0	0.95	-0.16		-0.14	0.22
Net Working Capital	-0.1	0.14	-0.35	-0.16	0.3	0.88	0.54	0.84	-0.45	0.99	-0.99	0.88	0.28	0.16	0.3	0.88	-0.45	0.43	0.92	0.64	-0.14	-0.24	1.0	-0.14		0.89
Net Receivables	0.24	-0.21	-0.27	-0.37	0.5	0.94	0.61	0.9	-0.17	0.89	-0.92	0.95	0.22	0.25	-0.13	0.95	-0.1	0.58	0.94	0.8	0.22	0.12	0.86	0.22	0.89

Click cells to compare fundamentals

Lucid Diagnostics Account Relationship Matchups

Lucid Diagnostics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	6.3M	15.7M	4.3M	8.4M	29.4M	30.9M
Net Tangible Assets	(5.3M)	(13.5M)	(24.1M)	19.6M	22.5M	23.7M
Retained Earnings	(5.5M)	(13.8M)	(41.9M)	(98.1M)	(150.7M)	(143.2M)
Accounts Payable	799.1K	2.1M	1.5M	1.1M	1.1M	1.3M
Total Current Assets	390.9K	1.4M	57.3M	24.4M	22.1M	19.4M
Common Stock	14.1K	14.1K	35K	41K	42K	28.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:

How To Invest In Lucid

Details

Is Lucid Stock a good investment?

Details

What is Lucid Diagnostics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.12)

Revenue Per Share

0.09

Quarterly Revenue Growth

0.497

Return On Assets

(1.01)

Return On Equity

(10.08)

The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lucid Capital Surpluse vs Capital Stock Analysis

Capital Surpluse vs Capital Stock

Capital Surpluse vs Capital Stock Correlation Analysis

Correlation Coefficient

Capital Surpluse

Capital Stock

Lucid Diagnostics fundamental ratios Correlations

Lucid Diagnostics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lucid Diagnostics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Capital Stock	+ 1.0	Other Stockholder Equity
Net Working Capital	+ 1.0	Net Invested Capital

Net Working Capital	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Invested Capital	- 0.98	Net Debt
Short Term Investments	- 0.96	Retained Earnings
Capital Stock	- 0.95	Other Liab
Other Stockholder Equity	- 0.95	Other Liab